TD Cowen analyst Josh Jennings has maintained their bullish stance on HUMA stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors including the promising progress of Humacyte’s Symvess product launch. The company has achieved 13 hospital VAC approvals, which is a significant increase from the previous quarter, indicating growing acceptance and potential for future sales growth. Additionally, the monthly revenue run rate for Symvess has shown improvement, with July sales surpassing the total sales for the first half of 2025, suggesting a positive trend in commercial traction.
Despite the second quarter product sales falling short of some high market expectations, they were in line with TD Cowen’s estimates, reflecting a more realistic outlook. The company’s collaboration with a large medical technology firm also adds potential for future revenue streams through the application of Humacyte’s bioengineered tissue in cardiovascular and vascular fields. Although the company reported a net loss, the reduction in losses compared to the previous year and a solid cash position provide a stable financial foundation to support ongoing operations and growth initiatives.
In another report released today, BTIG also maintained a Buy rating on the stock with a $7.00 price target.